In the latest trading session, 0.97 million Humacyte Inc (NASDAQ:HUMA) shares changed hands as the company’s beta touched 1.36. With the company’s most recent per share price at $3.10 changed hands at -$0.12 or -3.79% at last look, the market valuation stands at $398.61M. HUMA’s current price is a discount, trading about -221.61% off its 52-week high of $9.97. The share price had its 52-week low at $2.81, which suggests the last value was 9.35% up since then.
Analysts gave the Humacyte Inc (HUMA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.29. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended HUMA as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Humacyte Inc’s EPS for the current quarter is expected to be -0.25.
Humacyte Inc (NASDAQ:HUMA) trade information
Instantly HUMA was in red as seen in intraday trades today. With action -17.39%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -38.65%, with the 5-day performance at -17.39% in the red. However, in the 30-day time frame, Humacyte Inc (NASDAQ:HUMA) is -32.80% down.
The consensus price target for the stock as assigned by Wall Street analysts is 8, meaning bulls need an upside of 61.25% from its recent market value. According to analyst projections, HUMA’s forecast low is 6 with 10 as the target high. To hit the forecast high, the stock’s price needs a -222.58% plunge from its current level, while the stock would need to soar -93.55% for it to hit the projected low.
Humacyte Inc (HUMA) estimates and forecasts
4 analysts are of the opinion that Humacyte Inc’s revenue for the current quarter will be 800.25k. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
The 2025 estimates are for Humacyte Inc earnings to decrease by -26.30%, but the outlook for the next 5-year period is at 41.70% per year.
Humacyte Inc (NASDAQ:HUMA)’s Major holders
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 4.3693% or 4.73 million shares worth $22.7 million as of 2024-06-30.
Among Mutual Funds, the top two as of Nov 30, 2024 were SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. With 2.7 shares estimated at $8.35 million under it, the former controlled 2.14% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 2.06% of the shares, roughly 2.59 shares worth around $8.02 million.
